Clinical Trial Update: Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and immunogenicity of a booster dose of the H5N1 influenza vaccine; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• H5N1 influenza vaccine (influenza vaccine H5N1)

Snippet

Sponsor: Novartis Vaccines | Conditions: Avian Influenza | Phase 2 | Status: COMPLETED